NL-OMON23166尚未招募不适用
CLINICAL TRIAL TO EVALUATE SAFETY AND DOSE RESPONSE USING THE C2 CRYOBALLOON SWIPE ABLATION SYSTEM FOR THE TREATMENT OF BARRETT’S ESOPHAGUS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients with flat-type (Paris type 0-IIb) BE esophagus, with an indication for ablation therapy, meaning:
- •Diagnosis of LGD or HGD in BE (confirmed by baseline histopathological analysis), OR
排除标准
- •1.Esophageal stenosis or stricture preventing advancement of a therapeutic endoscope.
- •2.Any endoscopically visualized lesion such as ulcers, masses or nodules. Neoplastic nodules must first be treated with ER >6 weeks prior to planned treatment under this protocol.
研究者
相似试验
已完成
不适用
CLINICAL TRIAL TO EVALUATE SAFETY AND DOSE RESPONSE USING THE C2 CRYOBALLOON SWIPE ABLATION SYSTEM FOR THE TREATMENT OF BARRETT*S ESOPHAGUSBarrett's esophagus10017990esophageal cancerNL-OMON43223C2Therapeutics, Marcia Wachna18
招募中
不适用
Clinical trial to evaluate safety and dose response of the C2 CryoBalloon 180 Ablation SystemBarrett's esophagus<br />Barrett's dysplasia<br />Cryoablation<br />Cryotherapy<br /><br />Barrett slokdarm<br />Barrett neoplasie<br />Cryoablatie<br />CryotherapieNL-OMON28028C2 Therapeutics, Inc.25
已完成
不适用
Clinical trial to evaluate safety and dose response using the C2 CryoBalloonTM 180 Ablation system for the treatment of dysplastic Barrett*s esophagusesophageal cancerNL-OMON48956C2 Therapeutics, contactpersoon Marcia Wachna25
招募中
1 期
TS-FARMEV StudySolid tumors refractory to oncospecific treatment.RPCEC00000112Center for Genetic Engineering and Biotechnology (CIGB), in Havana.
进行中（未招募）
不适用
Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positive. - LIRA-BEUCTR2010-020387-38-ITBristol-Myers Squibb International Corporation300